Toronto Stock Exchange Symbol: CYT
MONTREAL, April 18 /CNW/ - CryoCath Technologies Inc., the global leader
in cryotherapy products to treat cardiovascular disease, today announced that
additional data on the Company's proprietary Arctic Front(R) catheter system
to treat Atrial Fibrillation (AF) was presented at the German Cardiac
Society's 73rd Annual Conference, the premier annual event for German
cardiologists, in Mannheim, Germany on April 12, 2007.
CryoCath sponsored a cryotherapy symposium featuring presentations by Dr.
Julian Chun and Dr. Matthais Antz from Asklepios Klinikum St. Georg in
Hamburg, Professor Burghard Schumacher from Rhvn-Klinikum AG in Bad Neustadt
and Professor Luc Jordaens from Erasmus Thoraxcentre in Rotterdam, to a
standing room only audience. Dr. Antz and Professors Schumacher and Jordaens
presented acute and 3-month data on a total of 150 patients following ablation
procedures. Acutely, over 90% of the pulmonary veins were successfully
isolated. When pulmonary vein isolation was achieved, 75% of patients were
AF-free after three or more months following a single procedure.
In the series of patients presented in Mannheim, no stenosis, thrombosis,
esophageal perforation or stroke were reported at any of the centers. As well,
no left atrial flutters, a common occurrence following RF ablation procedures,
were observed. In less than 5% of cases, phrenic nerve palsy, predominantly
asymptomatic, was reported. The rate of incidence observed is consistent with
that recorded in both the U.S. and European feasibility studies. All reported
incidences of phrenic nerve palsy have resolved as of the presentations in
Mannheim last week.
"This commercial European data demonstrates that Arctic Front is a
practical tool for the treatment of AF in a typical EP-lab setting. As well it
demonstrates that it is feasible to isolate pulmonary veins in a very high
percentage of cases using Arctic Front alone," said Jan Keltjens, President
and CEO of CryoCath. "Furthermore, the fact that two out of three centers that
presented data at the cryotherapy symposium are successfully using a single
Arctic Front balloon to perform cryoablation is a testament to the versatility
of this product. It reinforces our belief that it has the potential to
dominate the treatment of this disease and demonstrates that it has the
potential to bring a simple, safe and effective therapy to many millions of AF
patients around the world."
CryoCath - www.cryocath.com - is a medical technology company that leads
the world in cryotherapy products to treat cardiovascular disease. With a
priority focus on providing physicians with a complete solution of catheter
and surgical products to treat cardiac arrhythmias, CryoCath has multiple
products approved in the U.S., across Europe and several ROW countries. The
Company is developing additional products to expand its pipeline of products
to treat cardiac arrhythmias.
This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at www.sedar.com under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.
For further information:
For further information: visit our website at www.cryocath.com, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail: firstname.lastname@example.org